ERBB2 and gastric cancer: HER2 is overexpressed in 20–30% of breast and gastric cancers and expression is correlated with a poor prognosis.6,7,8,9 A number of HER2-targeted agents have been developed, including trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and lapatinib.